HR Execs on the Move

Makindus

www.makindus.com

 
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.makindus.com
  • 3805 Old Easton Road
    Doylestown, PA USA 18902
  • Phone: 267.291.4912

Executives

Name Title Contact Details

Similar Companies

Liberty BioSecurity

Liberty BioSecurity’s multi-disciplinary research teams transform life science discoveries into global-class, industry leading solutions.

Vytelle

With Vytelle, cattle producers increase accuracy of feed intake and bodyweight measurement, improve certainty of genetic selection and accelerate progress.

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.

Atreca

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients` immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today`s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health.

Zealand Pharma

Changing lives with next generation peptide therapeutics